1. Comparison of whole-genome and immunoglobulin-based circulating tumor DNA assays in diffuse large B-cell lymphoma.
- Author
-
Merryman RW, Rhoades J, Xiong K, Redd RA, Antel K, An HH, McDonough M, Guerrero L, Crnjac A, Sridhar S, Blewett T, Cheng J, Dahi PB, Nieto Y, Joyce RM, Chen YB, Herrera AF, Armand P, Murakami M, and Adalsteinsson VA
- Abstract
Competing Interests: Reid W. Merryman—Advisory board: Genmab, Adaptive Biotechnologies, Bristol Myers Squibb, Abbvie, Inteillia, Epizyme; consulting: Alphasights; institutional research funding: Merck, Bristol Myers Squibb, Genmab, Genentech/Roche. Yago Nieto—Consulting: Affimed, Novonordisk; research funding: Novartis, Biosecura, Astra‐Zeneca, Affimed, Takeda. Yi‐Bin Chen—Consulting: Incyte, Jasper, Gamida Cell, Daiichi, Celularity, Equilium, Actinium. Alex F. Herrera—Consulting: Bristol Myers Squibb, Genentech, Merck, Seattle Genetics, AstraZeneca, Karyopharm, ADC Therapeutics, Takeda, Tubulis, Genmab, Regeneron; research funding: Bristol Myers Squibb, Genentech, Merck, Seattle Genetics, KiTE Pharma, Gilead Sciences, AstraZeneca, ADC Therapeutics. Philippe Armand—Consulting: Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome, Regeneron, Epizyme, AstraZeneca, Genentech; research funding (institutional): Merck, BMS, Affimed, Adaptive, Roche, Tensha, Otsuka, Sigma Tau, Genentech, IGM, Kite; Honoraria: Merck, BMS. Mark Murakami—Advisory board: Novartis, CancerModels.org; research funding: Generate Biomedicines, Genentech/Roche. Viktor A. Adalsteinsson is a co‐inventor on a patent application covering MAESTRO (US 2023/0203568, pending) which has been licensed to Exact Sciences which was not involved in this study; receives research funding from Exact Sciences; and is a co‐founder and advisor to Amplifyer Bio which was not involved in this study. The remaining authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF